WO2018107376A1 - 一种人参皂苷Rh2的纯化方法 - Google Patents
一种人参皂苷Rh2的纯化方法 Download PDFInfo
- Publication number
- WO2018107376A1 WO2018107376A1 PCT/CN2016/109848 CN2016109848W WO2018107376A1 WO 2018107376 A1 WO2018107376 A1 WO 2018107376A1 CN 2016109848 W CN2016109848 W CN 2016109848W WO 2018107376 A1 WO2018107376 A1 WO 2018107376A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- enzyme reaction
- reaction solution
- ethyl acetate
- ethanol
- ginsenoside
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
Definitions
- the present invention relates to the technical field of a method for purifying ginsenoside monomer Rh2, and more particularly to a method for purifying an enzyme reaction solution for preparing Rh2 by catalyzing Rg3 with ⁇ -glucosidase.
- Ginsenoside is a triterpenoid compound mainly found in ginseng medicinal materials. It is regarded as the main component of pharmacological activity in ginseng. It has the treatment of cardiovascular and cerebrovascular diseases, improving immunity and anti-tumor. Anti-fatigue, antibacterial, anti-aging and other effects.
- ginsenoside monomers known to date, such as Rbl, Rb2, Rb3, Rc, Rd, Rgl, Rg2, Rg3, Rhl, Rh2 and Re.
- Ginsenoside Rh2 is the single component with the strongest anticancer activity in ginsenosides. It has a significant inhibitory effect on malignant cells, can effectively control the growth of malignant cells, and even convert malignant cells into normal cells. As the results of clinical trials have been reported successively, ginsenoside Rh2 is extremely satisfactory for the anti-cancer effect and is regarded as the most potential natural anticancer substance today.
- Ginsenoside Rh2 contained in ginseng is extremely rare, and Rh2 is not found in white ginseng, and the content in red ginseng is only one in 100,000, and extraction is very difficult, so the price is very expensive. Based on this, the current large-scale production of ginsenoside Rh2 is generally artificially prepared. It was found that the structure of ginsenoside Rg3 is only one more glycosyl than ginsenoside Rh2, so Rh2 can be obtained by hydrolyzing the extra sugar group in Rg3. Because the pharmacological activity and bioavailability of Rg3 are lower than Rh2, and the natural content of Rg3 is much higher than that of Rh2, the extraction is relatively easy.
- ⁇ -glucosidase is used to catalyze the hydrolysis of Rg3 to prepare Rh2.
- the enzyme reaction solution of this preparation method is further purified after completion of the reaction.
- most known purification treatment methods are those in which the enzyme reaction solution is filtered and then separated by macroporous resin or subjected to silica gel column chromatography, but the purification method is cumbersome, labor-intensive, and costly.
- an object of the present invention is to provide a novel purification method of ginsenoside Rh2 for purifying an enzyme reaction solution for preparing Rh2 by ⁇ -glucosidase-catalyzed Rg3.
- the technical problems that are cumbersome, labor-intensive, and costly in solving the existing purification methods are solved.
- the present invention provides a method for purifying ginsenoside Rh2, which is used for purifying an enzyme reaction solution for preparing Rh2 by ⁇ -glucosidase catalyzing Rg3, characterized in that: the enzyme is used in an extraction system.
- the reaction solution is extracted, and the upper layer solution is left after standing to be separated, and the upper layer solution is subjected to solvent recovery to obtain a Rh2 product;
- the extraction system is composed of ammonium sulfate, ethanol and ethyl acetate, and the ammonium sulfate is composed of
- the amount of the enzyme reaction solution is 2-20 g/100 ml, and the total volume of the ethanol and the ethyl acetate is 0.5-5 times the volume of the enzyme reaction solution, and the ethanol and the ethyl acetate are The volume ratio is 1:1-4.
- ginsenoside Rh2 since ammonium sulfate is insoluble in ethanol and ethyl acetate, it is preferred to separately add the components of the extraction system to the enzyme reaction solution.
- ammonium sulphate is first added to the enzyme reaction solution according to the ratio, and after being completely dissolved, ethanol and ethyl acetate are separately added according to the ratio, shaken, and then allowed to stand for stratification.
- the ammonium sulfate is used in an amount of 5-15 g/100 ml of the enzyme reaction solution.
- the ammonium sulfate is used in an amount of from 8 to 15 g per 100 ml of the enzyme reaction liquid.
- the ammonium sulfate is used in an amount of 8 g / 100 ml of the enzyme reaction liquid.
- the total volume of the ethanol and the ethyl acetate is 2-3 times the volume of the enzyme reaction solution.
- the total volume of the ethanol and the ethyl acetate is twice the volume of the enzyme reaction solution.
- the volume ratio of the ethanol to the ethyl acetate is 1:2-4.
- the volume ratio of the ethanol to the ethyl acetate is 1:2-3.
- the volume ratio of the ethanol to the ethyl acetate is 1:2.
- the purification method of the ginsenoside Rh2 provided by the invention has the advantages of simple operation, short consumption and low cost, and the method can be obtained by one-time extraction using a small amount of the extractant.
- the purified ginseng saponin monomer Rh2 with higher yield and purity is highly competitive in the market.
- Purification treatment target Bangtai Bioengineering (Shenzhen) Co., Ltd. uses bio-enzyme catalyzed method (using ginsenoside Rg3 as substrate, catalyzed preparation of Rh2 by ⁇ -glucosidase in the presence of DMSO and sodium phosphate buffer)
- the enzyme reaction solution prepared after sufficient reaction was determined by high performance liquid chromatography: the conversion rate of the enzyme-catalyzed reaction was 92.6% in terms of Rg3, and the purity of Rh2 in the enzyme reaction solution was 7.3%.
- the above enzyme reaction solution is purified according to the above purification process, wherein ammonium sulfate is added in an amount of 8 g / 100 ml of enzyme reaction solution, ethanol and ethyl acetate in a volume ratio of 1:2, ethanol and ethyl acetate
- the total volume added was 0.5 times (0.5 BV), 1 time (1 BV), 2 times (2 BV), 3 times (3 BV) and 5 times (5 BV) of the volume of the enzyme reaction solution, and the purified Rh2 product was measured.
- the yield and purity are shown in Table 1, respectively, and the extractant in the table refers to the total volume of ethanol and ethyl acetate.
- the above enzyme reaction solution is purified according to the above purification process, wherein the total volume of ethanol and ethyl acetate is twice the volume of the enzyme reaction solution, and the volume ratio of ethanol and ethyl acetate is 1:2.
- the amount of ammonium sulfate added is 2g / 100ml enzyme reaction solution (denoted as 2%), 5g / 100ml enzyme reaction solution (denoted as 5%), 8 g / 100ml enzyme reaction solution (recorded as 8%), 15g / 100 ml of the enzyme reaction solution (indicated as 15%) and 20 g/100 ml of the enzyme reaction solution (indicated as 20%), and the yield and purity of the purified Rh2 product were measured as shown in Table 3.
- Method A purifying the above enzyme reaction solution according to the above purification process, wherein ammonium sulfate is added in an amount of 8 g / 100 ml of the enzyme reaction solution, and the total volume of ethanol and ethyl acetate is added to the volume of the enzyme reaction solution. 2 times, the volume ratio of ethanol and ethyl acetate added is 1:2, and the three groups of enzyme reaction liquids are repeatedly purified and purified. The yields of the obtained Rh2 products are shown in Table 4, respectively.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
一种人参皂苷Rh2的纯化方法，用于纯化以β-葡萄糖苷酶催化Rg3制备Rh2的酶反应液，旨在解决现有纯化方法存在的操作繁琐、耗时耗力、且成本较高的技术问题。该纯化方法包括：用萃取体系对酶反应液进行萃取，静置分层后留取上层溶液，并对上层溶液进行溶剂回收，即得Rh2产品；萃取体系由硫酸铵、乙醇和乙酸乙酯组成，硫酸铵的用量为2-20g/100ml酶反应液，乙醇和乙酸乙酯的总体积量为酶反应液体积的0.5-5倍，并且乙醇和乙酸乙酯的体积比为1:1-4。
Description
一种人参皂苷 Rh2的纯化方法 技术领域
[0001] 本发明涉及人参皂苷单体 Rh2的纯化方法的技术领域， 特别涉及对以 β -葡萄糖 苷酶催化 Rg3制备 Rh2的酶反应液进行纯化的方法。
背景技术
[0002] 人参皂苷是一种三萜类化合物， 主要存在于人参属药材中， 被视为是人参中起 药理活性的主成分， 具有治疗心脑血管系统疾病、 提高机体免疫力、 抗肿瘤、 抗疲劳、 抗菌、 延缓衰老等作用。 现今已明确知晓的人参皂苷单体约有 40余种 ， 如 Rbl、 Rb2、 Rb3、 Rc、 Rd、 Rgl、 Rg2、 Rg3、 Rhl、 Rh2及 Re等。
[0003] 据大量研究发现， 在众多人参皂苷单体中以人参皂苷 Rh2的功效最为显著， 几 乎代表了人参里的全部正面功效。 人参皂苷 Rh2是人参皂苷中抗癌活性最强的单 一成分， 其对恶性细胞有着显著的抑制效果， 可以有效地控制恶性细胞的生长 ， 甚至将恶性细胞转化为正常细胞。 随着临床试验结果陆续地被报导出来， 人 参皂苷 Rh2对于抗癌的疗效极为惊人的满意， 被视为当今最具潜力的天然抗癌物 质。
[0004] 人参中含有的人参皂苷 Rh2极为稀少， 在白参中并未发现含有 Rh2， 而在红参 中的含量仅为十万分之一， 且提取十分困难， 因而价格十分昂贵。 基于此， 目 前人参皂苷 Rh2的大规模生产一般为人工制备。 研究发现， 人参皂苷 Rg3的结构 仅比人参皂苷 Rh2多了一个糖基， 因此可通过水解 Rg3中多出的糖基获得 Rh2。 又因 Rg3的药理活性及生物利用度均低于 Rh2， 且 Rg3的天然含量比 Rh2高很多， 提取相对容易， 故而， 工业上会采用 β-葡萄糖苷酶催化水解 Rg3来制备 Rh2。 为 了获得较为纯净的人参皂苷 Rh2， 在反应完成后， 还需对此种制备方法的酶反应 液进行进一步纯化处理。 目前已知的纯化处理方法多为将酶反应液过滤后经大 孔树脂分离或者过硅胶柱层析， 可是此种纯化方法操作繁琐、 耗吋耗力、 且成 本较高。
技术问题
[0005] 鉴于现有技术存在的上述不足， 本发明的目的在于提供一种人参皂苷 Rh2的新 的纯化方法， 用于对以 β-葡萄糖苷酶催化 Rg3制备 Rh2的酶反应液进行纯化， 旨 在解决现有的纯化方法存在的操作繁琐、 耗吋耗力、 且成本较高的技术问题。 问题的解决方案
技术解决方案
[0006] 为实现上述目的， 本发明提供了一种人参皂苷 Rh2的纯化方法， 用于纯化以 β- 葡萄糖苷酶催化 Rg3制备 Rh2的酶反应液， 其特征在于： 用萃取体系对所述酶反 应液进行萃取， 静置分层后留取上层溶液， 并对所述上层溶液进行溶剂回收， 即得 Rh2产品； 所述萃取体系由硫酸铵、 乙醇和乙酸乙酯组成， 所述硫酸铵的用 量为 2-20g/100ml所述酶反应液， 所述乙醇和所述乙酸乙酯的总体积量为所述酶 反应液体积的 0.5-5倍， 并且所述乙醇和所述乙酸乙酯的体积比为 1:1-4。
[0007] 在本发明提供的上述人参皂苷 Rh2的纯化方法中， 由于硫酸铵不溶于乙醇和乙 酸乙酯， 故宜将萃取体系的各组分分别加入到酶反应液中。 优选先按配比将硫 酸铵加入酶反应液中， 待溶解完全后再按配比分别加入乙醇和乙酸乙酯， 摇匀 后静置分层。
[0008] 优选地， 所述硫酸铵的用量为 5-15g/100ml所述酶反应液。
[0009] 更优选地， 所述硫酸铵的用量为 8-15g/100ml所述酶反应液。
[0010] 更优选地， 所述硫酸铵的用量为 8g/100ml所述酶反应液。
[0011] 优选地， 所述乙醇和所述乙酸乙酯的总体积量为所述酶反应液体积的 2-3倍。
[0012] 更优选地， 所述乙醇和所述乙酸乙酯的总体积量为所述酶反应液体积的 2倍。
[0013] 优选地， 所述乙醇和所述乙酸乙酯的体积比为 1:2-4。
[0014] 更优选地， 所述乙醇和所述乙酸乙酯的体积比为 1:2-3。
[0015] 更优选地， 所述乙醇和所述乙酸乙酯的体积比为 1:2。
发明的有益效果
有益效果
[0016] 与现有技术相比， 本发明提供的人参皂苷 Rh2的纯化方法具有操作简单、 耗吋 较短且成本低廉的优点， 该方法只需使用少量的萃取剂经一次性萃取便可获得 较高收率和纯度的人参皂苷单体 Rh2， 所获得的纯化产品极具市场竞争力。
本发明的实施方式
[0017] 下面结合具体实施例对本发明做进一步的详细说明， 以下实施例是对本发明的 解释， 本发明并不局限于以下实施例。
[0018] 纯化处理对象： 邦泰生物工程 （深圳） 有限公司采用生物酶催化法 （以人参皂 苷 Rg3为底物， 在 DMSO和磷酸钠缓冲液存在的条件下， 用 β-葡萄糖苷酶催化制 备 Rh2) 经充分反应后制备得到的酶反应液， 经高效液相色谱法测得： 以 Rg3计 ， 该次酶催化反应的转化率为 92.6%， 酶反应液中的 Rh2的纯度为 7.3%。
[0019] 对上述酶反应液的纯化过程如下：
[0020] 按配比向酶反应液中加入硫酸铵， 待溶解完全后再按配比加入乙醇和乙酸乙酯 ， 充分摇匀后静置分层， 下层为水相， 上层为有机相； 取上层的有机相置旋蒸 仪中旋蒸， 在 70°C条件下以 60rpm转速旋蒸至体积不再变化， 回收溶剂， 趁热过 滤， 再用 1%体积的纯水冲洗滤饼， 烘干后即得 Rh2产品。
[0021] 实施例 1
[0022] 乙醇和乙酸乙酯总用量优化对比
[0023] 按上述纯化流程对上述酶反应液进行纯化处理， 其中， 硫酸铵的加入量为 8g/l 00ml酶反应液， 乙醇和乙酸乙酯的体积比为 1:2， 乙醇和乙酸乙酯加入的总体积 量分别为酶反应液体积的 0.5倍 （0.5BV) 、 1倍 （1BV) 、 2倍 （2BV) 、 3倍 （3 BV) 和 5倍 （5BV) ， 测得纯化所得 Rh2产品的收率和纯度分别如表 1所示， 表中 萃取剂指代乙醇和乙酸乙酯的总体积量。
[0024] 表 1
[] [表 1]
[0025] 实施例 2
[0026] 乙醇和乙酸乙酯比例优化对比
[0027] 按上述纯化流程对上述酶反应液进行纯化处理， 其中， 硫酸铵的加入量为 8g/l 00ml酶反应液， 乙醇和乙酸乙酯加入的总体积量为酶反应液体积的 2倍， 乙醇和 乙酸乙酯加入的体积比分别为 1:1、 1:2、 1:3和 1:4， 测得纯化所得 Rh2产品的收率 和纯度分别如表 2所示， 表中醇 /酯指代乙醇和乙酸乙酯的体积比。
[0028] 表 2
[] [表 2]
[0029] 实施例 3
[0030] 硫酸铵用量优化对比
[0031] 按上述纯化流程对上述酶反应液进行纯化处理， 其中， 乙醇和乙酸乙酯加入的 总体积量为酶反应液体积的 2倍， 乙醇和乙酸乙酯加入的体积比为 1:2， 硫酸铵的 加入量分别为 2g/100ml酶反应液 （记为 2%) 、 5g/100ml酶反应液 （记为 5%) 、 8 g/100ml酶反应液 （记为 8%) 、 15g/100ml酶反应液 （记为 15%) 、 20g/100ml酶 反应液 （记为 20%) ， 测得纯化所得 Rh2产品的收率和纯度分别如表 3所示。
[0032] 表 3
[] [表 3]
[0033] 实施例 4
[0034] 与单纯用乙酸乙酯萃取的对比
[0035] 方法 A: 按上述纯化流程对上述酶反应液进行纯化处理， 其中， 硫酸铵的加入 量为 8g/100ml酶反应液， 乙醇和乙酸乙酯加入的总体积量为酶反应液体积的 2倍 ， 乙醇和乙酸乙酯加入的体积比为 1:2， 重复纯化处理三组酶反应液， 测得纯化
所得 Rh2产品的收率分别如表 4所示。
[0036] 方法 Β ·· 单纯用乙酸乙酯对上述酶反应液进行萃取， 重复萃取三次， 每次乙酸 乙酯加入的体积量为酶反应液体积的 2倍， 重复纯化处理三组酶反应液， 测得纯 化所得 Rh2产品的收率分别如表 4所示， 表中列出了三次萃取分别对应的收率。
[0037] 表 4
[] [表 4]
[0038]
Claims
权利要求书
一种人参皂苷 Rh2的纯化方法， 用于纯化以 β-葡萄糖苷酶催化 Rg3制 备 Rh2的酶反应液， 其特征在于： 用萃取体系对所述酶反应液进行萃 取， 静置分层后留取上层溶液， 并对所述上层溶液进行溶剂回收， 即 得 Rh2产品； 所述萃取体系由硫酸铵、 乙醇和乙酸乙酯组成， 所述硫 酸铵的用量为 2-20g/100ml所述酶反应液， 所述乙醇和所述乙酸乙酯 的总体积量为所述酶反应液体积的 0.5-5倍， 并且所述乙醇和所述乙酸 乙酯的体积比为 1:1-4。
根据权利要求 1所述的人参皂苷 Rh2的纯化方法， 其特征在于： 所述 硫酸铵的用量为 5-15g/100ml所述酶反应液。
根据权利要求 1所述的人参皂苷 Rh2的纯化方法， 其特征在于： 所述 硫酸铵的用量为 8-15g/100ml所述酶反应液。
根据权利要求 3所述的人参皂苷 Rh2的纯化方法， 其特征在于： 所述 硫酸铵的用量为 8g/100ml所述酶反应液。
根据权利要求 1所述的人参皂苷 Rh2的纯化方法， 其特征在于： 所述 乙醇和所述乙酸乙酯的总体积量为所述酶反应液体积的 2-3倍。
根据权利要求 5所述的人参皂苷 Rh2的纯化方法， 其特征在于： 所述 乙醇和所述乙酸乙酯的总体积量为所述酶反应液体积的 2倍。
根据权利要求 1所述的人参皂苷 Rh2的纯化方法， 其特征在于： 所述 乙醇和所述乙酸乙酯的体积比为 1:2-4。
根据权利要求 7所述的人参皂苷 Rh2的纯化方法， 其特征在于： 所述 乙醇和所述乙酸乙酯的体积比为 1:2-3。
根据权利要求 8所述的人参皂苷 Rh2的纯化方法， 其特征在于： 所述 乙醇和所述乙酸乙酯的体积比为 1:2。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/109848 WO2018107376A1 (zh) | 2016-12-14 | 2016-12-14 | 一种人参皂苷Rh2的纯化方法 |
| CN201680016127.XA CN108430596B (zh) | 2016-12-14 | 2016-12-14 | 一种人参皂苷Rh2的纯化方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/109848 WO2018107376A1 (zh) | 2016-12-14 | 2016-12-14 | 一种人参皂苷Rh2的纯化方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018107376A1 true WO2018107376A1 (zh) | 2018-06-21 |
Family
ID=62557687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2016/109848 WO2018107376A1 (zh) | 2016-12-14 | 2016-12-14 | 一种人参皂苷Rh2的纯化方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN108430596B (zh) |
| WO (1) | WO2018107376A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020215265A1 (zh) * | 2019-04-25 | 2020-10-29 | 邦泰生物工程(深圳)有限公司 | 稀有人参皂苷Rh3和Rk2混合物的制备方法及其混合物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020058805A1 (en) * | 2000-09-25 | 2002-05-16 | I-Hong Pan | Process for extracting glycoside using an aqueous two-phase system |
| CN101637667A (zh) * | 2009-08-19 | 2010-02-03 | 大连理工大学 | 一种三液相萃取天然产物有效成分的方法 |
| CN102058644A (zh) * | 2009-11-17 | 2011-05-18 | 天津天士力制药股份有限公司 | 人参次苷h提取物及其制备方法 |
| CN102094052A (zh) * | 2010-12-12 | 2011-06-15 | 大连理工大学 | 一种糖苷酶催化与盐析萃取偶联制备天然药物的方法 |
| KR20130113718A (ko) * | 2012-04-06 | 2013-10-16 | 재단법인 금산국제인삼약초연구소 | 인삼의 잎과 줄기로부터 진세노사이드 ｆ1의 분획정제방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO990397A0 (en) * | 1997-10-22 | 1997-11-13 | R.P. Scherer Holdings Pty Ltd | Clear solutions of herbal extracts |
| CN1648133A (zh) * | 2004-02-23 | 2005-08-03 | 黄亚平 | 人参皂甙rh2的制备方法 |
| CN101463061B (zh) * | 2007-12-21 | 2013-09-18 | 中国医学科学院药物研究所 | 三七中人参皂苷Rg1、Rb1及其总皂苷的制备方法 |
| KR101079293B1 (ko) * | 2009-03-27 | 2011-11-04 | 건국대학교 산학협력단 | 고온성 베타-글리코시다아제를 이용한 희귀 진세노사이드의제조방법 |
| CN101919901B (zh) * | 2009-06-10 | 2012-01-11 | 赵全成 | 皂角总苷元在制备α-葡萄糖苷酶抑制剂的药物中的应用 |
| CN102125590B (zh) * | 2011-03-11 | 2012-08-29 | 浙江大学 | 含人参皂苷Rg1的三七有效组分及制备方法与用途 |
| CN104561219A (zh) * | 2014-12-16 | 2015-04-29 | 江南大学 | 一种酶促合成人参皂苷Rh2的方法 |
| CN105296587B (zh) * | 2015-11-18 | 2019-02-22 | 湖南工程学院 | 一种转化人参皂苷Rb1制备稀有人参皂苷CK的方法与应用 |
-
2016
- 2016-12-14 CN CN201680016127.XA patent/CN108430596B/zh active Active
- 2016-12-14 WO PCT/CN2016/109848 patent/WO2018107376A1/zh active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020058805A1 (en) * | 2000-09-25 | 2002-05-16 | I-Hong Pan | Process for extracting glycoside using an aqueous two-phase system |
| CN101637667A (zh) * | 2009-08-19 | 2010-02-03 | 大连理工大学 | 一种三液相萃取天然产物有效成分的方法 |
| CN102058644A (zh) * | 2009-11-17 | 2011-05-18 | 天津天士力制药股份有限公司 | 人参次苷h提取物及其制备方法 |
| CN102094052A (zh) * | 2010-12-12 | 2011-06-15 | 大连理工大学 | 一种糖苷酶催化与盐析萃取偶联制备天然药物的方法 |
| KR20130113718A (ko) * | 2012-04-06 | 2013-10-16 | 재단법인 금산국제인삼약초연구소 | 인삼의 잎과 줄기로부터 진세노사이드 ｆ1의 분획정제방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108430596A (zh) | 2018-08-21 |
| CN108430596B (zh) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101775056B (zh) | 一种从黄芪中提取、分离和纯化黄芪甲苷的方法 | |
| CN101747388B (zh) | 一种同时从石榴皮提取安石榴苷和鞣花酸的方法 | |
| CN106083940B (zh) | 一种从枳实中提取高纯度新橙皮苷的方法 | |
| CN103059095B (zh) | 一种黄姜资源综合高效利用的绿色提取技术 | |
| KR101566589B1 (ko) | 진세노사이드 f2의 함량이 증가된 발효 홍삼의 제조방법 및 상기 방법으로 제조된 발효 홍삼 추출물 | |
| CN106967142B (zh) | 一种同时提取罗汉果甜苷v、ⅵ和11-o基苷v的方法 | |
| CN104721245A (zh) | 多酶酶解制作人参提取成份的方法 | |
| CN108383890A (zh) | 一种高含量人参皂苷Re提取物的制备方法 | |
| CN103040902A (zh) | 一种纯化野生党参皂苷的新方法 | |
| CN101108871A (zh) | 从大枣中提取环磷酸腺苷的工艺方法 | |
| CN102372750A (zh) | 一种同时制备芍药内酯苷和芍药苷的方法 | |
| CN102492667A (zh) | 一种酶制剂及其用于提取黄柏小檗碱的应用和方法 | |
| CN110882285A (zh) | 桑黄中活性物质的高效制备方法 | |
| CN106480156A (zh) | 一种酶催化二醇组人参皂苷大规模生产稀有人参皂苷的方法 | |
| CN102286058A (zh) | 一种制备高纯度甘草酸的方法 | |
| CN104940280A (zh) | 一种应用酶制剂提取葛根总黄酮的方法 | |
| CN104140931A (zh) | 一种阿达青霉发酵原人参二醇制备稀有人参皂苷ck的方法 | |
| WO2018107376A1 (zh) | 一种人参皂苷Rh2的纯化方法 | |
| CN111304272B (zh) | 一种利用轮枝镰孢菌转化三七茎叶皂苷制备人参稀有皂苷的方法 | |
| CN104711301A (zh) | 一种淫羊藿素的制备方法 | |
| CN104263763A (zh) | 一种从虎杖中提取白藜芦醇的新方法 | |
| CN106480157A (zh) | 一种酶催化三醇组人参皂苷大规模生产稀有人参皂苷的方法 | |
| CN101683387B (zh) | 一种药物及其制备方法与应用 | |
| CN105968150B (zh) | 7-o-乙基莫诺苷的制备方法 | |
| CN105237594A (zh) | 一种从竹柳皮中提取水杨苷的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16923875 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 16923875 Country of ref document: EP Kind code of ref document: A1 |